BRAINAURORA-B (06681) surged over 5% again, trading at HK$6.51 by press time, up 3.33%, with a turnover of HK$48.33 million.

The company announced that its wholly-owned subsidiary, Zhijingling Technology, has joined a national key R&D program—"Research on Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases"—as a key collaborator. The project, titled "Establishment and Scenario-Based Application of Key Digital Diagnosis and Treatment Technologies for Intracranial Atherosclerotic Stenosis (ICAS)-Related Cognitive Disorders Based on Deep Reasoning Large Models," has recently commenced.

Additionally, Zhijingling Technology, in collaboration with Xuanwu Hospital of Capital Medical University, has received approval to establish the "Beijing Key Laboratory of Digital Healthcare for Cognitive Disorders."

The national program focuses on addressing diagnostic and therapeutic challenges for cognitive disorders caused by ICAS. It aims to develop deep reasoning large models and a closed-loop management system for early disease screening, risk prediction, and intervention tools. As a core technology provider, BRAINAURORA-B will lead the development of deep reasoning models and digital diagnosis platforms for ICAS-related cognitive disorders.